Direct oral anticoagulants in patients undergoing cardioversion: insight from randomized clinical trials

Submitted: December 16, 2016
Accepted: April 10, 2017
Published: May 18, 2017
Abstract Views: 2098
PDF: 1106
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.


Anticoagulation, reducing the risk of thromboembolic events in patients undergoing cardioversion, is a cornerstone of peri-cardioversion management in patients with atrial fibrillation. We aimed to analyse published data on the efficacy and safety of direct oral anticoagulants (DOACs) in patients undergoing cardioversion. We performed a systematic review of randomized prospective clinical trials (RCTs) comparing DOACs with warfarin and reporting data on post-cardioversion outcomes of interest. Outcomes of interest were stroke, systemic thromboembolic events and major bleeding. We reviewed a total of six RCTs including 3900 cardioversions performed using a DOAC for thromboembolic prophylaxis. These studies reported a low incidence overall of adverse outcomes associated with the use of DOACs (around 1% in all studies, except the ROCKET post-hoc study which included ablation procedures). The incidence rate of adverse events during DOAC treatment was found to be very similar to that observed with warfarin anticoagulation. In RCTs DOAC treatment in patients undergoing cardioversion appears to be effective and safe. However, because evidence in this clinical setting is still weak, observational reports could be useful in providing further data about peri-procedural outcomes.



PlumX Metrics


Download data is not yet available.


How to Cite

Di Fusco, Stefania Angela, Furio Colivicchi, Nadia Aspromonte, Marco Tubaro, Alessandro Aiello, and Massimo Santini. 2017. “Direct Oral Anticoagulants in Patients Undergoing Cardioversion: Insight from Randomized Clinical Trials”. Monaldi Archives for Chest Disease 87 (1).